sorafenib has been researched along with Orphan Diseases in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kasper, B | 1 |
| Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM | 1 |
| Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN | 1 |
| Figlin, R; Moldawer, NP | 1 |
| Bihari, C; Gupta, NL; Jain, D; Rastogi, A; Sarin, SK | 1 |
2 review(s) available for sorafenib and Orphan Diseases
| Article | Year |
|---|---|
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed | 2013 |
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
1 trial(s) available for sorafenib and Orphan Diseases
| Article | Year |
|---|---|
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome | 2013 |
2 other study(ies) available for sorafenib and Orphan Diseases
| Article | Year |
|---|---|
Desmoid tumor: A focus set on a challenging but understudied rare disease.
Topics: Autophagy; Fibromatosis, Aggressive; Humans; Rare Diseases; Sorafenib | 2019 |
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiography, Abdominal; Rare Diseases; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |